Financial Perspectives Inc trimmed its position in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 18.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 4,952 shares of the company’s stock after selling 1,130 shares during the quarter. Financial Perspectives Inc’s holdings in ARK Genomic Revolution ETF were worth $117,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Hemington Wealth Management lifted its position in ARK Genomic Revolution ETF by 44.6% in the fourth quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock worth $30,000 after purchasing an additional 404 shares during the period. Union Bancaire Privee UBP SA acquired a new stake in shares of ARK Genomic Revolution ETF during the 4th quarter valued at $45,000. National Bank of Canada FI lifted its position in shares of ARK Genomic Revolution ETF by 28.4% during the 3rd quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock valued at $106,000 after acquiring an additional 920 shares during the last quarter. IHT Wealth Management LLC acquired a new stake in shares of ARK Genomic Revolution ETF during the 3rd quarter valued at $203,000. Finally, Hilltop Holdings Inc. acquired a new stake in shares of ARK Genomic Revolution ETF during the 3rd quarter valued at $237,000.
ARK Genomic Revolution ETF Price Performance
Shares of BATS:ARKG opened at $29.49 on Wednesday. The firm’s 50 day moving average is $25.66 and its two-hundred day moving average is $25.29.
ARK Genomic Revolution ETF Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
See Also
- Five stocks we like better than ARK Genomic Revolution ETF
- P/E Ratio Calculation: How to Assess Stocks
- Affirm Hits Profitability—Here’s What Investors Should Watch
- How to Calculate Options Profits
- There’s Room to Chase These 3 Stocks Trading Near 52-Week Highs
- Stock Market Upgrades: What Are They?
- 3 Stocks With Robust Growth Outlooks Insiders Are Buying
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.